A phase II study of 4'-epirubicin in the treatment of poor-risk Kaposi's sarcoma and AIDS.
Twenty-six patients with poor-risk Kaposi's sarcoma and AIDS were treated with epirubicin 90 mg/m2 intravenously every 3 weeks. One patient achieved complete response and 10 achieved partial response (overall response rate 42.3%). The median time to treatment failure was 22 weeks. The dose-limiting toxicity was neutropenia.
Shepherd
F A
FA
Department of Medicine, Toronto General Hospital, Canada.
Burkes
R L
RL
Paul
K E
KE
Goss
P E
PE
D000163:Acquired Immunodeficiency Syndrome / Q000150:complications*; D000328:Adult; D000368:Aged; D004341:Drug Evaluation; D015251:Epirubicin / Q000008:administration & dosage / Q000009:adverse effects / Q000627:therapeutic use*; D006801:Humans; D008297:Male; D008875:Middle Aged; D009503:Neutropenia / Q000139:chemically induced; D009864:Ontario; D011446:Prospective Studies; D012074:Remission Induction; D012514:Sarcoma, Kaposi / Q000188:drug therapy* / Q000209:etiology / Q000401:mortality; D015996:Survival Rate
D015251:Epirubicin